AMENDMENTS

Claims 1-88 (canceled)

89. (Previously presented) A method for determining the risk of tumor recurrence or spread in a patient suffering from prostate cancer, said method comprising:

(a) determining a BAG-1 gene expression level in a cancerous prostate tissue sample from said patient; and

(b) comparing said BAG-1 gene expression level in said patient to a reference BAG-1 gene expression level, said reference BAG-1 gene expression level being a level of BAG-1 gene expression above which correlates with an increased risk of tumor recurrence or spread and below which correlates with a decreased risk of tumor recurrence or spread, thereby determining the risk of tumor recurrence or spread in said patient.

90. (Previously presented) The method of claim 89 , wherein said tumor spread comprises tumor metastasis.

91. (Previously presented) The method of claim 89 , wherein said BAG-1 gene expression level is determined by measuring a BAG-1 protein level.

92. (Previously presented) The method of claim 91 , wherein said BAG-1 protein level is determined with an antibody specific for BAG-1 protein.

93. (Previously presented) The method of claim 89 , wherein said BAG-1 gene encodes a nuclear BAG-1 protein.

94. (Previously presented) The method of claim 89, wherein said BAG-1 gene encodes a cytosolic BAG-1 protein.

95. (Previously presented) The method of claim 89, wherein said BAG-1 gene encodes a protein selected from the group consisting of BAG-1, BAG-1N, BAG-1M and BAG-1L.

96. (Previously presented) The method of claim 89, wherein said BAG-1 gene expression level is determined using an immunoassay.

2

97. (Previously presented) The method of claim 96, wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

98. (Previously presented) The method of claim 89 , wherein said reference BAG-1 gene expression level is a level of BAG-1 gene expression above which correlates with increased risk of tumor recurrence or spread in a first group of patients compared to a second group of patients, said second group of patients having BAG-1 gene expression levels below said reference level.

99. (Previously presented) A method for determining a prognosis of survival in a patient suffering from prostate cancer, said method comprising:

(a) determining a BAG-1 gene expression level in a cancerous prostate tissue sample from said patient; and

(b) comparing said BAG-1 gene expression level in said patient to a reference BAG-1 gene expression level, said reference BAG-1 gene expression level being a level of BAG-1 gene expression above which correlates with decreased survival and below which correlates with increased survival, thereby determining a prognosis of survival in said patient.

100. (Previously presented) The method of claim 99 , wherein said survival is overall survival.

101. (Previously presented) The method of claim 99 , wherein said survival is distant metastasis-free survival.

102. (Previously presented) The method of claim 99, wherein said BAG-1 gene expression level is determined by measuring a BAG-1 protein level.

103. (Previously presented) The method of claim 102, wherein said BAG-1 protein level is determined with an antibody specific for BAG-1 protein.

104. (Previously presented) The method of claim 99, wherein said BAG-1 gene encodes a nuclear BAG-1 protein.

105. (Previously presented) The method of claim 99, wherein said BAG-1 gene encodes a cytosolic BAG-1 protein.

106. (Previously presented) The method of claim 99, wherein said BAG-1 gene encodes a protein selected from the group consisting of BAG-1, BAG-1N, BAG-1M and BAG-1L.

107. (Previously presented) The method of claim 99, wherein said BAG-1 gene expression level is determined using an immunoassay.

108. (Previously presented) The method of claim 107, wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

109. (Previously presented) The method of claim 99, wherein said reference BAG-1 gene expression level is a level of BAG-1 gene expression above which correlates with decreased survival in a first group of patients compared to a second group of patients, said second group of patients having BAG-1 gene expression levels below said reference level.

110. (Previously presented) The method of claim 95, wherein said BAG-1 gene encodes BAG-1.

111. (Withdrawn) The method of claim 95, wherein said BAG-1 gene encodes BAG-1N.

112. (Withdrawn) The method of claim 95, wherein said BAG-1 gene encodes BAG-1M.

113. (Withdrawn) The method of claim 95, wherein said BAG-1 gene encodes BAG-1L.

114. (Previously presented) The method of claim 106, wherein said BAG-1 gene encodes BAG-1.

115. (Withdrawn) The method of claim 106, wherein said BAG-1 gene encodes BAG-1N.

116. (Withdrawn) The method of claim 106, wherein said BAG-1 gene encodes BAG-1M.

117. (Withdrawn) The method of claim 106, wherein said BAG-1 gene encodes BAG-1L.